-$0.16 Earnings Per Share Expected for Entera Bio Ltd. (NASDAQ:ENTX) This Quarter

Equities research analysts expect Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) to announce earnings per share of ($0.16) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Entera Bio’s earnings. Entera Bio posted earnings of ($0.43) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 62.8%. The business is scheduled to report its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Entera Bio will report full-year earnings of ($0.85) per share for the current financial year, with EPS estimates ranging from ($0.91) to ($0.78). For the next year, analysts anticipate that the company will report earnings of ($0.95) per share, with EPS estimates ranging from ($1.07) to ($0.83). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Entera Bio.

Entera Bio (NASDAQ:ENTX – Get Rating) last posted its earnings results on Tuesday, March 8th. The company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.02. Entera Bio had a negative net margin of 2,134.33% and a negative return on equity of 59.83%. During the same quarter in the previous year, the business earned ($0.11) earnings per share.

ENTX has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Entera Bio from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Tuesday, January 11th. B. Riley decreased their target price on shares of Entera Bio from $11.00 to $6.00 in a research report on Monday, January 24th.

NASDAQ:ENTX opened at $2.45 on Monday. Entera Bio has a 52 week low of $1.72 and a 52 week high of $8.68. The firm has a 50 day moving average of $2.46 and a 200 day moving average of $2.90. The stock has a market capitalization of $58.07 million, a price-to-earnings ratio of -5.33 and a beta of 1.64.

Several hedge funds and other institutional investors have recently bought and sold shares of ENTX. Morgan Stanley raised its holdings in shares of Entera Bio by 145.6% in the third quarter. Morgan Stanley now owns 5,378 shares of the company’s stock worth $25,000 after buying an additional 3,188 shares during the last quarter. Altium Wealth Management LLC purchased a new position in shares of Entera Bio in the fourth quarter worth $33,000. Jane Street Group LLC acquired a new stake in shares of Entera Bio in the third quarter worth $54,000. Renaissance Technologies LLC acquired a new stake in shares of Entera Bio in the fourth quarter worth $113,000. Finally, ARK Investment Management LLC increased its stake in shares of Entera Bio by 1.2% in the fourth quarter. ARK Investment Management LLC now owns 690,922 shares of the company’s stock worth $1,945,000 after acquiring an additional 7,915 shares during the period. 23.98% of the stock is owned by institutional investors and hedge funds.

About Entera Bio (Get Rating)

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

Further Reading